{
    "organizations": [],
    "uuid": "22c4bd493ed91fdc90658051becf1d3d28235a7d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-destiny-pharma-says-on-track-to-de/brief-destiny-pharma-says-on-track-to-deliver-phase-2b-headline-data-in-h2-2019-for-xf-73-idUSFWN1RP05W",
    "ord_in_thread": 0,
    "title": "BRIEF-Destiny Pharma Says On Track To Deliver Phase 2B Headline Data In H2 2019 For Xf-73",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 12 (Reuters) - Destiny Pharma PLC:\n* WELL FUNDED AND ON TRACK TO DELIVER PHASE 2B HEADLINE DATA IN H2 2019 FOR LEAD ASSET, XF-73, A NOVEL ANTI-MICROBIAL\n* FY LOSS BEFORE INCOME TAX 3.2 MILLION POUNDS VERSUS 1.4 MILLION POUNDS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-12T15:30:00.000+03:00",
    "crawled": "2018-04-13T17:40:07.017+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "destiny",
        "pharma",
        "plc",
        "well",
        "funded",
        "track",
        "deliver",
        "phase",
        "2b",
        "headline",
        "data",
        "h2",
        "lead",
        "asset",
        "novel",
        "fy",
        "loss",
        "income",
        "tax",
        "million",
        "pound",
        "versus",
        "million",
        "pound",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}